How Intratumoral Injection Targets Solid Tumors

Intratumoral injection is exactly what it sounds like: delivering a drug, virus, immune-stimulating molecule, or other therapeutic agent directly into a tumor rather than sending it through the bloodstream. The approach can concentrate a drug inside the tumor at levels tens of times higher than intravenous delivery achieves, while exposing healthy organs to far less of the agent. Once a niche technique, it has become a serious pillar of modern oncology, particularly in immunotherapy, where activating the immune system locally can trigger responses against cancer elsewhere in the body.

The Concentration Advantage

The core rationale for injecting a drug straight into a tumor is simple: you get more drug where you want it and less where you don’t. Early pharmacokinetic work comparing intratumoral and intravenous routes found that drug concentrations inside the tumor were 10 to 80 times higher after direct injection, while organ exposure was lower.¹ Studies using polymer-based drug carriers confirmed the same pattern: both tumor concentrations and the ratio of tumor-to-organ drug levels improved substantially compared to intravenous delivery.²

This matters practically because many effective cancer drugs are limited by what they do to normal tissue. Chemotherapy agents damage the heart, kidneys, and gut lining. Immune-activating drugs can cause dangerous inflammatory reactions throughout the body. If you can keep most of the drug penned inside the tumor, you get the anticancer punch with a fraction of the collateral damage. That trade-off has driven a surge of interest in local delivery for agents that are simply too potent to pour into the bloodstream at the doses needed to reach the tumor.³

What Gets Injected

The list of agents that have been tried intratumorally is long and growing. It includes conventional chemotherapy drugs, oncolytic viruses, immune checkpoint antibodies, innate immune agonists, cytokine-encoding genetic material, and even living immune cells. Each class exploits the local delivery advantage differently.

Oncolytic Viruses

The best-known intratumoral therapy is talimogene laherparepvec, commonly called T-VEC. It is a genetically engineered herpes simplex virus that selectively replicates in tumor cells, kills them, and promotes antitumor immunity.⁴ Approved for advanced melanoma, T-VEC is injected directly into skin lesions. The virus bursts cancer cells open, releasing tumor-specific proteins that the immune system can then recognize, essentially turning the tumor into its own vaccine.

Chemotherapy Agents

Injecting chemotherapy drugs directly into a tumor is older than most people realize. Classic cytotoxic drugs like doxorubicin and 5-fluorouracil have been formulated for local delivery using hydrogels that act as slow-release depots. In one study, a hydrogel loaded with 5-fluorouracil maintained therapeutic drug concentrations inside the tumor while preventing the systemic toxicity the drug is notorious for.⁵ Work with doxorubicin showed a similar story: a hydrogel formulation achieved comparable tumor-killing effect to a plain solution but with much lower drug levels in the bloodstream, avoiding the acute heart toxicity that makes systemic doxorubicin so risky.⁶

Cytokines and Genetic Payloads

Cytokines are signaling molecules that can wake up the immune system, but injecting them intravenously often causes severe side effects like dangerously high fevers and plummeting blood pressure. Delivering them locally sidesteps that problem. Researchers have injected mRNA encoding cytokines like interleukin-12 and interferon-alpha directly into tumors, producing strong local immune activation, expansion of cancer-targeting T cells, and even immune memory that protected against tumor recurrence.⁷ Viral vectors carrying cytokine genes have also been tested in melanoma patients, with evidence that the encoded protein (GM-CSF in this case) was produced at the injection site for weeks after treatment.⁸ Another study using a vaccinia virus encoding interleukin-2 detected mRNA expression for up to three weeks after each injection, even as the patients’ immune systems generated antibodies against the virus itself.⁹

Innate Immune Agonists

Some of the most exciting intratumoral work involves drugs that prod the innate immune system into action. STING agonists, for example, activate a molecular alarm system inside cells. When injected into pancreatic tumors in mice, a high-potency STING agonist reprogrammed the tumor’s immune-suppressive environment, boosting both T cell activity and the behavior of myeloid cells that normally help tumors hide from the immune system. The injected tumors also became sensitive to checkpoint blockade drugs that had previously failed on their own.¹⁰

The Abscopal Effect

Perhaps the most compelling promise of intratumoral therapy is what happens at sites you never injected. When a locally treated tumor releases its contents and the immune system mounts a targeted response, that response can travel through the body and attack distant metastases. This phenomenon, called the abscopal effect, was once a rare curiosity. Intratumoral immunotherapy is making it more common, at least in preclinical models.

In one study, a single-dose injectable nanovaccine embedded in a hydrogel reduced immune suppression in the local tumor environment and triggered both local and distant tumor regression, including against orthotopic brain tumors far from the injection site.¹¹ Another approach combined an intratumoral immunoadjuvant gel with cryoablation (freezing the tumor) in checkpoint-inhibitor-resistant mouse models of colorectal and breast cancer. Responders typically showed complete regression of both the treated and untreated tumors in 90-day survival studies.¹²

These results help explain why intratumoral therapy is viewed as more than a local treatment for accessible tumors. The idea is to use one tumor as a training ground for the immune system, then let that trained immunity hunt down cancer cells wherever they are. Translating the abscopal effect reliably into human patients remains a major challenge, but early clinical signals are encouraging enough that dozens of trials are testing this concept.

Pairing Intratumoral Therapy with Systemic Drugs

One of the most active research areas is combining intratumoral injections with systemic immune checkpoint inhibitors like anti-PD-1 or anti-PD-L1 antibodies. The logic is straightforward: the intratumoral agent heats up the local immune environment, while the checkpoint inhibitor releases the brakes on T cells throughout the body. Together, they can overcome resistance that neither achieves alone.¹³

A striking demonstration came from a study using a TLR9 agonist called SD-101 injected into tumors that had stopped responding to anti-PD-1 therapy. The combination led to complete, durable rejection of essentially all injected tumors and a majority of distant, uninjected tumors across multiple mouse cancer models.¹⁴ Radiation therapy has also been paired with intratumoral injections to similar effect: combining radiation with intratumoral IL-2 and a multifunctional nanoparticle significantly improved tumor response, tumor-specific immune memory, and abscopal effects beyond what any single or dual combination achieved.¹⁵

Checkpoint inhibitors can also be given locally. In a bladder cancer mouse model, CT-scan-guided intratumoral delivery of an anti-PD-L1 antibody alongside curcumin maintained anticancer effects while sharply reducing the colitis (intestinal inflammation) that systemic anti-PD-L1 therapy commonly causes.¹⁶ This hints at a future where even drugs we currently think of as systemic could be given locally to spare patients from side effects.

How the Injection Is Actually Done

For surface tumors like melanoma skin lesions, intratumoral injection is as simple as inserting a needle under direct vision. For deeper tumors, the procedure relies on imaging guidance. Ultrasound, CT, and MRI are all used to steer the needle into the right spot. A case series assessing image-guided intratumoral immunotherapy across a range of tumor types and organs found the technique was feasible and reported no adverse events related to needle insertion or biopsy.¹⁷

For brain tumors, standard needle injection distributes the drug only about 5 millimeters from the catheter tip, which barely covers a small fraction of many tumors. A technique called convection-enhanced delivery uses positive pressure to push the drug outward through the tissue, extending the distribution radius to about 6 centimeters from the tip, a roughly 4,000-fold increase in the volume covered.¹⁸ The pump delivers fluid at very slow rates to avoid tissue damage while ensuring uniform spread.

Physical Barriers Inside the Tumor

Tumors are not hollow bags waiting to be filled. They are dense, high-pressure environments. Solid tumors tend to have elevated interstitial fluid pressure, caused by leaky blood vessels, absent or dysfunctional lymphatic drainage, and a stiff matrix of collagen and other structural proteins.¹⁹ In pancreatic cancers, this pressure is particularly problematic, with studies showing it is dominated by gel-like solid components of the tissue rather than free fluid, making conventional drug penetration extremely difficult.²⁰

This high internal pressure means that when you inject liquid into a tumor, it can be squeezed right back out along the needle track or into surrounding tissue. The drug may pool in one area rather than spreading evenly, leaving parts of the tumor untreated. Injection technique, needle placement, injection speed, and the physical properties of the drug formulation all influence how uniformly the agent distributes. A review examining these factors noted that the drug’s behavior after injection depends heavily on the interplay between formulation viscosity, injection volume, and the tumor’s own microenvironment.²¹

Keeping the Drug Inside the Tumor

Because tumors tend to push injected liquid back out, a major engineering effort has gone into formulations that stay put. Hydrogels that are liquid at room temperature but gel inside the body can act as drug depots, slowly releasing their payload over days or weeks. Nanoparticles, microspheres, and even microneedle patches have all been developed for the same purpose: holding the drug in the tumor long enough to work.²²

The hydrogel approach has been particularly well-studied. Thermosensitive hydrogels remain fluid during injection but solidify at body temperature, trapping the drug in place. The doxorubicin hydrogel study mentioned earlier showed this strategy can match the tumor-killing effect of a plain drug solution while dramatically lowering how much drug escapes into the bloodstream.²³ The 5-fluorouracil hydrogel depot similarly kept most of the drug inside the tumor over the experimental period.²⁴ These sustained-release formulations also reduce the number of injections patients need, which matters for comfort and practicality in deep or hard-to-reach tumors.

Safety and Side Effects

Intratumoral therapy is generally better tolerated than systemic delivery of the same agents, but it is not without risks. One review noted that even with local injection, patients can experience symptoms resembling a cytokine storm within minutes: rigors, shaking chills, rapid heartbeat, and drops in blood pressure.²⁵ These reactions likely happen because some fraction of the injected immune-activating agent leaks into the systemic circulation, or because the local immune response itself generates signals that spill over into the rest of the body.

Multiple preclinical studies have confirmed that intratumoral delivery reduces systemic toxicity compared to intravenous delivery of the same drug, with lower organ exposure and fewer off-target effects.²⁶ The image-guided injection case series found no complications from the injection procedure itself.²⁷ But the overall safety profile depends heavily on which agent is injected. An oncolytic virus will have different risks than a checkpoint antibody or a chemotherapy drug, and the location of the tumor adds its own hazards. Injecting into a lung tumor, for instance, carries a risk of pneumothorax that a skin lesion does not.

Historical Roots

The idea of injecting something into a tumor to trigger an immune response is not new. In 1891, William B. Coley injected streptococcal bacteria into a patient with inoperable cancer, reasoning that the resulting infection might shrink the tumor. It worked, and over the next four decades, Coley injected more than 1,000 cancer patients with bacteria or bacterial products at Memorial Hospital in New York.²⁸ Coley’s approach was crude by modern standards, and the results were inconsistent enough that the technique fell out of favor as surgery and radiation advanced. But the principle he stumbled onto, that local immune activation inside a tumor could fight cancer, is the same principle driving today’s intratumoral immunotherapy trials.

Intratumoral Therapy in Veterinary Oncology

Dogs and cats develop many of the same cancers humans do, and veterinary oncology has become an active testing ground for intratumoral approaches. A clinical study in dogs with advanced cancers used intratumoral injections of poly-ICLC, a synthetic immune-stimulating molecule. Among dogs that completed at least 12 weeks of treatment, three out of five had stable tumors, one had a partial response, and one progressed. Side effects were generally mild, occurring in 10 of 14 patients.²⁹ These veterinary studies serve a dual purpose: they provide treatment options for companion animals and generate real-world data on safety, dosing, and immune responses in a species that shares many biological features with humans, often faster and with fewer regulatory hurdles than human trials allow.

Cellular Therapies Going Local

CAR-T cell therapy, in which a patient’s own immune cells are engineered to attack cancer, has transformed treatment for certain blood cancers but struggles against solid tumors. The cells have trouble getting into dense tumor tissue, and the immunosuppressive environment inside solid tumors can shut them down. One proposed solution is injecting the engineered cells directly into the tumor. Novel delivery strategies, including local-regional infusion and even biomaterial scaffolds that carry CAR-T cells, are being explored to overcome the limitations of standard intravenous infusion.³⁰ Placing the cells where they need to work, rather than hoping they navigate through the bloodstream and infiltrate a hostile microenvironment on their own, could be the missing piece for solid tumor CAR-T therapy.